1. Home
  2. VERA vs FTRE Comparison

VERA vs FTRE Comparison

Compare VERA & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vera Therapeutics Inc.

VERA

Vera Therapeutics Inc.

HOLD

Current Price

$55.40

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Fortrea Holdings Inc.

FTRE

Fortrea Holdings Inc.

HOLD

Current Price

$17.80

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VERA
FTRE
Founded
2016
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.5B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
VERA
FTRE
Price
$55.40
$17.80
Analyst Decision
Strong Buy
Hold
Analyst Count
11
8
Target Price
$76.60
$12.64
AVG Volume (30 Days)
1.9M
1.4M
Earning Date
11-05-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$2,759,900,000.00
Revenue This Year
N/A
$3.17
Revenue Next Year
N/A
$0.11
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.88
52 Week Low
$18.53
$3.97
52 Week High
$56.05
$20.26

Technical Indicators

Market Signals
Indicator
VERA
FTRE
Relative Strength Index (RSI) 82.73 76.76
Support Level $47.22 $17.11
Resistance Level $51.19 $18.29
Average True Range (ATR) 2.94 0.95
MACD 0.63 0.17
Stochastic Oscillator 97.57 86.18

Price Performance

Historical Comparison
VERA
FTRE

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

About FTRE Fortrea Holdings Inc.

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Share on Social Networks: